Vitamin D3 + K2: How It Actually Works and What the Evidence Says
Most people taking vitamin D3 are missing half the equation. The calcium problem doesn't end with absorption, it ends with where that calcium actually goes.
90-second summary
Read the transcript
Taking D3 without K2 leaves a real gap, and here is why that matters. Most people know vitamin D3 increases calcium absorption in the gut, by as much as 30 to 40 percent compared to a deficient state. What most people do not know is that absorbing more calcium is only the first step. Once that calcium enters your bloodstream, two proteins determine where it ends up: osteocalcin, which binds calcium into bone, and Matrix Gla Protein, which blocks calcium from depositing in arterial walls. Both proteins require vitamin K2 to activate. Without K2, neither works reliably. So D3 raises blood calcium, and K2 directs it to bone rather than soft tissue. They work on different steps of the same pathway, which is why pairing them makes biological sense. Clinical trials support this. A randomized controlled trial in 244 postmenopausal women found that MK-7 combined with D3 improved bone mineral density significantly more than D3 alone. Separate research shows MK-7 reduces circulating uncarboxylated MGP, a recognized marker of vascular calcification risk. The cardiovascular evidence is still building, but the bone data is consistent. For dosing, most adults do well with 1,000 to 2,000 IU of D3 daily and MK-7 at 90 to 180 mcg, taken together with a fat-containing meal since both are fat-soluble. If you are on warfarin, talk to your doctor before adding K2. Read the full breakdown at Elm and Rye to see the clinical data and exact dosing guidance.
The Mechanism (Skip This If You Just Want the Dose)
Vitamin D3 (cholecalciferol) is converted in the liver to 25-hydroxyvitamin D, then in the kidneys to its active form: 1,25-dihydroxyvitamin D (calcitriol). Calcitriol binds to vitamin D receptors in the gut and signals the upregulation of calcium-binding proteins, primarily calbindin-D9k. This can increase intestinal calcium absorption by 30-40% compared to a deficient state, according to data reviewed by the NIH Office of Dietary Supplements.
Here is where most D3 articles stop. They treat calcium absorption as the finish line. It isn't.
When you flood the bloodstream with calcium, two proteins determine where it ends up: osteocalcin and Matrix Gla Protein (MGP). Both require carboxylation to function. Both depend entirely on vitamin K2 (specifically menaquinone-7, or MK-7) to activate the enzyme gamma-glutamyl carboxylase. Uncarboxylated osteocalcin cannot bind calcium into bone matrix. Uncarboxylated MGP cannot inhibit calcium from depositing in arterial walls. Without K2, the calcium D3 pulls into circulation has no reliable guidance system.
This is the biological case for pairing them. D3 increases the calcium load in your blood. K2 activates the proteins that direct that calcium into bone and away from soft tissue. They are not interchangeable, they work on different steps of the same pathway. Taking high-dose D3 without K2 does not automatically cause arterial calcification, but the theoretical risk is real enough that several cardiologists and researchers have flagged it as worth addressing, particularly in people supplementing above 2,000 IU daily over extended periods.
What the Clinical Evidence Actually Shows
The honest summary: the D3 + K2 combination has solid mechanistic support and a growing body of clinical data, but most trials are small and few are long enough to show hard cardiovascular endpoints.
| Study Type | Sample Size | Finding | Dose Used |
|---|---|---|---|
| RCT (bone density, postmenopausal women) | 244 | MK-7 + D3 significantly improved bone mineral density vs. D3 alone | 180 mcg MK-7 + 800 IU D3 |
| Observational cohort (Rotterdam Study) | 4,807 | High dietary K2 intake associated with reduced cardiovascular mortality | Dietary K2, variable |
| RCT (arterial stiffness) | 244 | MK-7 supplementation reduced dp-ucMGP (inactive MGP marker) and improved arterial flexibility | 180 mcg MK-7 daily |
| Meta-analysis (D3 and calcium absorption) | Multiple trials | D3 deficiency correction increases calcium absorption by 30-40% | 800-2,000 IU D3 |
| RCT (VitaK-CAC trial, arterial calcification) | 200 | MK-7 did not significantly slow coronary calcification progression vs. placebo | 360 mcg MK-7 daily |
The VitaK-CAC trial is worth noting because it complicates the narrative. Higher-dose MK-7 did not significantly slow existing coronary calcification. Prevention and reversal are different problems, and the evidence for reversal is weak. What the data does support more consistently is the role of K2 in bone health and in reducing circulating uncarboxylated MGP, a recognized biomarker of vascular calcification risk.
How to Take It Correctly
Form and timing matter here more than with most supplements.
Vitamin D3 specifics:
- Standard maintenance dose: 1,000-2,000 IU daily for adults with normal baseline levels
- Deficiency correction (under physician guidance): 4,000-5,000 IU daily for 8-12 weeks
- Take with a fat-containing meal. D3 is fat-soluble and absorption drops significantly without dietary fat present.
- Test serum 25-hydroxyvitamin D before and after supplementing. Target range is generally 40-60 ng/mL.
Vitamin K2 specifics:
- MK-7 (menaquinone-7) is the preferred form. It has a half-life of approximately 72 hours vs. 1-2 hours for MK-4, meaning once-daily dosing is realistic.
- Effective dose range: 90-180 mcg MK-7 daily for most adults
- Also fat-soluble. Take it with the same meal as D3.
- If you are on warfarin or any vitamin K antagonist anticoagulant, do not add K2 without direct physician supervision. K2 directly affects coagulation pathways.
My take: The Elm & Rye Vitamin D3 supplement uses cholecalciferol (D3) specifically rather than ergocalciferol (D2) because the clinical evidence consistently shows D3 raises serum 25-hydroxyvitamin D more effectively and sustains it longer. That form choice is not cosmetic, it reflects a real difference in how the two forms behave in the liver conversion step.
Living in San Francisco, I get less sun than most people assume. The fog belt here is no joke. From October through April, I can go entire weeks without meaningful UVB exposure, even when I'm running the Crissy Field path or hitting the courts at the Presidio Wall. I started testing my 25-hydroxyvitamin D annually about four years ago and found I was consistently sitting at 28-32 ng/mL, below the range most sports medicine clinicians consider optimal for musculoskeletal recovery. Adding 2,000 IU D3 with MK-7 daily brought me to 52 ng/mL within three months.
For a broader look at how D3 fits into a full micronutrient protocol, the best vitamins and minerals for men over 40 covers the full picture well.
The Honest Limitations
The mechanistic argument for D3 + K2 is strong. The clinical evidence for hard outcomes, fewer fractures, measurably lower cardiovascular events, is still catching up.
Most K2 trials are short (under 3 years), underpowered, and conducted in specific populations (postmenopausal women, dialysis patients). Extrapolating those findings to healthy adults in their 30s and 40s requires some inference. The bone density data is the most consistent. The cardiovascular data is suggestive but not conclusive.
Individual response to D3 supplementation also varies significantly based on genetics. Polymorphisms in the VDR gene (vitamin D receptor) and the GC gene (vitamin D binding protein) affect how efficiently people convert and utilize D3. Some people need 4,000 IU to reach 50 ng/mL; others get there on 1,000 IU. Testing removes the guesswork.
Toxicity from D3 is real but rare at doses under 4,000 IU daily in healthy adults. Hypercalcemia risk rises meaningfully above 10,000 IU daily taken chronically. K2 at standard doses has no established toxicity ceiling, with the exception of drug interactions noted above.
The Bottom Line
D3 increases calcium absorption; K2 activates the proteins that put that calcium where it belongs. Taking one without the other, especially at higher D3 doses, leaves a biological gap that the evidence suggests is worth closing.
---
FAQ
Does vitamin K2 actually prevent arterial calcification?
K2 activates Matrix Gla Protein, which inhibits calcium from depositing in arterial walls, and studies show it reduces circulating uncarboxylated MGP. However, current evidence supports risk reduction and slowing progression more than reversal of existing calcification.
The VitaK-CAC trial found no significant reduction in coronary artery calcium scores with high-dose MK-7 over two years, which suggests K2 is more relevant as a preventive tool than a corrective one. Starting earlier matters.
What is the difference between MK-4 and MK-7 forms of K2?
MK-7 has a half-life of roughly 72 hours, making it far more practical for once-daily supplementation, while MK-4 clears the bloodstream within 1-2 hours and requires multiple doses. Most of the recent clinical trial data on arterial and bone outcomes used MK-7 at 90-180 mcg daily.
MK-4 appears in some older Japanese studies at pharmacological doses (45 mg, not mcg), which is a very different context from standard supplementation. For daily use, MK-7 is the better-supported choice.
Can I get enough vitamin D from sunlight alone?
In theory, yes. In practice, geography, skin tone, season, sunscreen use, and time outdoors all reduce realistic sun-derived D3 synthesis significantly. People living above 35 degrees latitude (which includes most of the northern US) produce essentially no vitamin D from sunlight between November and March.
For anyone in a fog-heavy or northern city, or anyone who works indoors most of the day, supplementation is a more reliable strategy than sun exposure alone. Testing your baseline 25-hydroxyvitamin D level is the only way to know where you actually stand.